What We're Reading: Page 271
Industry reads hand-picked by our editors
Mar 13, 2018
Mar 12, 2018
-
TechCrunch
Corporate bio VCs are backing more rounds and making bigger bets
-
Xconomy
Despite pharma ties, some patient groups protest high drug prices
-
The New York Times
Ask your doctor. Until then, here’s a word from our sitcom.
-
The Wall Street Journal
Cures welcome at FDA
Mar 09, 2018
-
The New York Times
Merck C.E.O. Ken Frazier on death row cases and the corporate soul
-
CNBC
The quest for the blockbuster Alzheimer’s drug has stalled, but there's another option
-
Boston Business Journal
Under SEC scrutiny, Bedford’s Ocular Therapeutix plans FDA do-over
-
Bloomberg
Diabetes drug developer Hua picks Hong Kong for IPO
Mar 08, 2018
-
Bloomberg BNA
Pharma class is in session more and more
-
Reuters
Sanofi may seek U.S. approval for Dengvaxia despite Philippines outrage
-
CNN
Cancer treatment guidelines questioned in new study
-
Xconomy
Prevail gets $75M for Parkinson’s gene therapy, bolstering NY biotech
-
Associated Press
FDA did not issue new statement on vaccines and autism
Mar 07, 2018
-
Fortune
How stale is innovation in drug discovery? Think: 5-year-old yogurt.
-
Medical Marketing & Media
Xbox for Docs: Pharma backs AR games for use in physician learning
-
Boston Business Journal
State's biotech IPO class of 2017 gets mixed reviews from investors
Mar 06, 2018
-
The Boston Globe
A path forward for experimental drug treatments
-
Bloomberg Gadfly
Dermira reminds investors what binary means in biotech
-
Associated Press
FDA chief wants more mail inspectors to stem opioid influx
Mar 05, 2018
-
Reuters
China's Tasly to list biotech arm in $1 billion Hong Kong IPO: sources
-
Chemical & Engineering News
Why can’t the drug industry solve its gender diversity problem?
-
Regulatory Focus
May on Brexit: UK should remain part of EMA
-
PBS
Gene therapy was a boy’s last chance to stop leukemia. And it worked.
Previous
